# Systematic critical appraisal of GRADE recommendations for prostate cancer staging

**Authors:** Dayana Sáenz, Ana Marcela Torres, Rodrigo Pardo, Wilfredo Donoso

PMC · DOI: 10.7705/biomedica.7653 · Biomédica · 2025-05-30

## TL;DR

This paper evaluates the quality of prostate cancer staging guidelines using the AGREE II tool and finds significant variation in their methodological quality.

## Contribution

The study systematically appraises GRADE recommendations for prostate cancer staging using AGREE II, highlighting quality gaps.

## Key findings

- The AGREE II domain 'clarity of presentation' had the highest score (mean = 71.59%).
- Significant heterogeneity was observed in the methodological quality of the guidelines.
- Five guidelines met the proposed AGREE II cutoff scores for quality.

## Abstract

Prostate cancer staging is necessary to determine tumor extent. In recent years, new and more accurate imaging modalities that could provide a better framework for patient management have emerged. They are currently incorporated into the prostate cancer guideline recommendations. Clinical practice guidelines are important for implementing clinical research findings and high-quality evidence-based recommendations.

To review and evaluate the quality of evidence underpinning the categorization of prostate cancer staging guidelines using the AGREE II tool.

Systematic searches were performed on the PubMed, BiGG, and Epistemonikos databases. In addition, repositories and clinical practice guidelines websites were hand searched to identify GRADE recommendations for prostate cancer staging published in the last five years. The quality of clinical practice guidelines was assessed using the AGREE II tool. Recommendations and the certainty of evidence were also summarized.

Seven guidelines that met the selection criteria were included. A narrative analysis of the staging recommendations and evidence mapping was performed. The AGREE II domain “clarity of presentation” had the highest score (mean = 71.59%), whereas “applicability” had the lowest score (mean = 45.15%). Five guidelines met the proposed AGREE II cutoff scores and provided staging and diagnostic recommendations.

Significant heterogeneity was observed in the methodological quality of the guidelines included, along with common deficits regarding applicability and stakeholder involvement. Thus, more rigorous and high-quality guidelines need to be developed to facilitate their implementation by clinicians in daily practice.

## Linked entities

- **Diseases:** prostate cancer (MONDO:0005159)

## Full-text entities

- **Diseases:** tumor (MESH:D009369), Prostate cancer (MESH:D011471)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12306965/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12306965/full.md

## References

29 references — full list in the complete paper: https://tomesphere.com/paper/PMC12306965/full.md

---
Source: https://tomesphere.com/paper/PMC12306965